Filing Details
- Accession Number:
- 0001209191-18-057930
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-11-09 16:02:45
- Reporting Period:
- 2018-11-07
- Accepted Time:
- 2018-11-09 16:02:45
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1131324 | Genomic Health Inc | GHDX | Services-Medical Laboratories (8071) | 770552594 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1649167 | Frederic Pla | 301 Penobscot Dr. Redwood City CA 94063 | Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-11-07 | 36,633 | $27.00 | 72,171 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2018-11-07 | 6,867 | $27.48 | 79,038 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-11-07 | 2,100 | $80.86 | 76,938 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-11-07 | 700 | $81.44 | 76,238 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-11-07 | 3,657 | $82.87 | 72,581 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-11-07 | 700 | $83.86 | 71,881 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-11-07 | 13,916 | $85.00 | 57,965 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-11-07 | 18,477 | $85.49 | 39,488 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-11-07 | 3,781 | $86.61 | 35,707 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-11-07 | 100 | $88.59 | 35,607 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-11-07 | 69 | $89.60 | 35,538 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) Holding | Disposition | 2018-11-07 | 36,633 | $0.00 | 36,633 | $27.00 |
Common Stock | Employee Stock Option (right to buy) Holding | Disposition | 2018-11-07 | 6,867 | $0.00 | 6,867 | $27.48 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
20,567 | 2026-02-16 | No | 4 | M | Direct | |
49,253 | 2027-01-31 | No | 4 | M | Direct |
Footnotes
- Includes an aggregate of 18,734 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 7, 2018.
- Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- Represents weighted average sale price. Actual sale prices ranged from $80.00 to $80.90.
- Represents weighted average sale price. Actual sale prices ranged from $81.00 to $81.70.
- Represents weighted average sale price. Actual sale prices ranged from $82.00 to $82.96.
- Represents weighted average sale price. Actual sale prices ranged from $83.04 to $84.00.
- Represents weighted average sale price. Actual sale prices ranged from $84.25 to $85.11.
- Represents weighted average sale price. Actual sale prices ranged from $85.25 to $86.00.
- Represents weighted average sale price. Actual sale prices ranged from $86.50 to $86.87.
- Represents actual sale price.
- The option became exercisable as to 25% of the shares on February 16, 2017, and became exercisable as to 1/48th of the shares each full month thereafter.
- The option became exercisable as to 25% of the shares on January 31, 2018, and becomes exercisable as to 1/48th of the shares each full month thereafter.